Vseobecna Fakultni Nemocnice V Praze
- Address
- lock Available on a paid plan
Neoplasms and Prostate Cancer Research
At Vseobecna Fakultni Nemocnice V Praze, the Urologicka klinika is conducting clinical research in oncology focused on neoplasms, especially prostate cancer. The studies are centered on improving treatment outcomes for men with high-risk localized and locally advanced disease, with attention to both disease control and long-term effectiveness.
- Evaluating new hormone-based cancer therapies for prostate cancer
- Studying treatment approaches for high-risk localized and locally advanced prostate cancer
- Assessing the safety and effectiveness of therapies used alongside standard care
This research landscape includes work on darolutamide and apalutamide, reflecting a strong focus on testing whether newer treatments can improve cancer control and support better outcomes for patients receiving radiation or surgery.
Advanced Treatment Strategies in High-Risk Prostate Cancer
Clinical trials at this Prague site are examining how androgen deprivation therapy and related targeted oncology treatments may improve care for men with high-risk localized or locally advanced prostate cancer. The overall goal is to strengthen treatment effectiveness while tracking important safety outcomes.
- Testing whether adding apalutamide to standard treatment can improve cancer control
- Comparing treatment strategies around radiation therapy and surgery
- Measuring outcomes linked to metastasis-free survival and tumor response
The site’s research is especially relevant for patients with aggressive forms of prostate cancer, where investigators are looking for ways to delay progression and improve the results of current treatment pathways.
Ongoing Oncology Studies in Prostate Cancer Care
Research at Ke Karlovu 6 is concentrated on cancer care within urology, with a clear emphasis on prostate cancer. These studies are designed to explore whether newer treatment combinations can enhance response, support better disease control, and provide useful safety information for clinical practice.
- Investigating continuation of darolutamide in participants already exposed to the treatment
- Assessing apalutamide combined with standard hormonal therapy
- Focusing on improved outcomes for men with high-risk localized and locally advanced prostate cancer
Across the three trials, the main theme is refining prostate cancer treatment through better therapeutic combinations and clearer evidence on how well these approaches work in patients with more advanced or higher-risk disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 11 therapeutic areas and 15 of 95 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 94 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International4trials
lock +7 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Vseobecna Fakultni Nemocnice V Praze
lock Showing 1 of 46 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 95 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Paclitaxel | 7 | Unknown | 2017-09-20 | 2026-05-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.